Literature DB >> 19122249

Profile and prevalence of clopidogrel resistance in patients of acute coronary syndrome.

Sandeep Kumar1, Ram K Saran, Aniket Puri, Nishant Gupta, Rishi Sethi, W R Surin, Madhu Dikshit, Sudhanshu K Dwivedi, Varun S Narain, Vijay K Puri.   

Abstract

UNLABELLED: Recently reports of a variable platelet response to aspirin and potential resistance to therapy have emerged with thienopyridines group of drugs. However the data available on clopidogrel resistance is scarce. The present study was initiated to prospectively evaluate the prevalence of clopidogrel resistance in patients of acute coronary syndrome(ACS) presently on dual anti platelet therapy by using an established method of optical platelet aggregation. We studied 39 patients of ACS, who were on clopidogrel 300 mg bolus followed by 75 mg per day for 3 days along with aspirin 325 mg per day. Fasting blood samples were assessed using optical platelet aggregation (Chronolog Corp, USA). Clopidogrel resistance was defined as <10% decrease from baseline in platelet aggregation. Clopidogrel semi-responders were defined as 10-29% ( <30%) decrease from baseline in platelet aggregation. Clopidogrel non-responders were defined as a composite of resistant and semi-responders. A baseline mean platelet aggregation obtained from 18 healthy subjects was 63.8 +/- 14.75% with 5 mu and 68.8 +/-13.91% with 10 mu of Adenosine Diphosphate. Hence, the definition of clopidogrel resistance was set as aggregation of >57% with 5 mu ADP and >61.9% with 10 mu ADP (< 10% decrease from baseline). The definition of clopidogrel semi-responder was set as aggregation of >or=45% with 5 mu ADP and >or=48% with 10 mu ADP (10-29% decrease from baseline). The mean platelet aggregation with 5 mu and 10 mu of Adenosine Diphosphate in the patient group was 30.77 +/- 17.19% and 35.71 +/- 17.0% respectively. Based on these criteria, 2.54% patients were found to be clopidogrel resistant, 12.7% were clopidogrel semi-responders and 84.7% were clopidogrel responders. On comparison of clopidogrel responders with non-responders, females ( p=0.07) and patients with higher serum triglyceride levels (p=0.08), had a trend to be more inclined towards clopidogrel non-responders. All other parameters tested namely age, smoking, diabetes, hypertension, obesity, cholesterol, hemoglobin, platelet count, ejection fraction and concurrent drug intake did not show any statistically significant difference among the groups.
CONCLUSIONS: This study shows that clopidogrel resistant and clopidogrel semi-responders do occur in Indian patients with ACS and there are no reliable clinical predictors for this condition. The diagnosis therefore relies primarily on laboratory tests.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 19122249

Source DB:  PubMed          Journal:  Indian Heart J        ISSN: 0019-4832


  5 in total

Review 1.  Clopidogrel resistance: the way forward.

Authors:  Shuvanan Ray
Journal:  Indian Heart J       Date:  2014-10-07

2.  Oral antiplatelet therapy and platelet inhibition: An experience from a tertiary care center.

Authors:  Jamshed J Dalal; Aarti Digrajkar; Alap Gandhi
Journal:  Indian Heart J       Date:  2016-01-14

3.  Incidence of major adverse cardiovascular events with genotype test guided antiplatelet treatment strategy after percutaneous coronary intervention.

Authors:  S Ramesh; S Socrates; M A Rajasekaran; N Senguttuvan
Journal:  Indian Heart J       Date:  2020-09-09

4.  Study of platelet aggregation in acute coronary syndrome with special reference to metabolic syndrome.

Authors:  Rudrajit Paul; Amit K Banerjee; Shantanu Guha; Utpal Chaudhuri; Srabani Ghosh; Jayati Mondal; Ramtanu Bandyopadhyay
Journal:  Int J Appl Basic Med Res       Date:  2013-07

5.  Clinical safety profile of ticagrelor compared to clopidogrel in 1208 patients: Real world evidence.

Authors:  Viveka Kumar; Vivek Kumar; Kajal Kumari; K K Talwar; Divya Prasad; Sunil Agarwal; M S Yadav; Hamed Bashir; Suman Jatain; S K Gupta
Journal:  Egypt Heart J       Date:  2018-06-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.